RPRX
Royalty Pharma plc
RPRX offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over RPRX overall, supported by stronger modeled upside and stronger valuation.
RPRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Weak |
RPRX's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
RPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $68.97 | — |
| Cheap | 15x | $22.76 | -67% |
| Fair | 23x | $34.85 | -49% |
| Expensive | 44x | $66.74 | -3.2% |
| Current | 45x | $68.97 | — |
Historical ranges are pointers, not guarantees.
RPRX's PE is in its expensive range at 45x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over RPRX in the historical PE scenario, which offers more potential upside but is not a forecast.
RPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| -- | |
| Limited | |
| High |
Analysts expect RPRX's earnings to grow, with its revenue and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
RPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.95 | +292% |
| Q3 2026 | $1.52 | -13% |
| Q2 2026 | $1.87 | -18% |
| Q1 2026 | $1.90 | -22% |
| Q4 2025 | $1.78 | -6.8% |
| Q3 2025 | $1.75 | -32% |
| Q2 2025 | $2.29 | +52% |
| Q1 2025 | $2.45 | +38% |
| Q4 2024 | $1.91 | -25% |
RPRX's earnings per share have fallen from their peak: $1.52 over the past year, against $3.36 in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over RPRX on earnings, with more consistent year-over-year improvement.
RPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.1M | +13% |
| Q2 2026 | $674.1M | +16% |
| Q1 2026 | $630.6M | +11% |
| Q4 2025 | $622M | +4.8% |
| Q3 2025 | $609.3M | +7.9% |
| Q2 2025 | $578.7M | +7.7% |
| Q1 2025 | $568.2M | 0% |
| Q4 2024 | $593.6M | -0.4% |
RPRX's revenue has grown year over year for seven quarters in a row: $690M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | -11 points |
| Q2 2026 | 20% | -17 points |
| Q1 2026 | 89% | -4.7 points |
| Q4 2025 | 62% | +1.5 points |
| Q3 2025 | 70% | -60 points |
| Q2 2025 | 36% | -14 points |
| Q1 2025 | 94% | +107 points |
| Q4 2024 | 61% | -42 points |
RPRX has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over RPRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
RPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $686.1M | -2.4% |
| Q2 2026 | $728.5M | +100% |
| Q1 2026 | $718.2M | +20% |
| Q4 2025 | $827.1M | +11% |
| Q3 2025 | $702.6M | -0.1% |
| Q2 2025 | $364M | -45% |
| Q1 2025 | $596.1M | -10% |
| Q4 2024 | $742.5M | -3.9% |
RPRX's free cash flow has been positive every quarter for six years: $3B over the past year, up 23% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over RPRX on cash flow, with more consistent year-over-year improvement.
RPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +105K shares |
| 1 year | -0.5% | -2.6M shares |
| 3 years | -7.3% | -44.1M shares |
| 5 years | -8.3% | -50.1M shares |
| Available history | +58% | +205M shares |
RPRX has 557M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $86.3M |
| Q2 2026 | $44.6M |
| Q1 2026 | $50.1M |
| Q4 2025 | $80.5M |
| Q3 2025 | $146.5M |
| Q2 2025 | $291.6M |
| Q1 2025 | $708.8M |
| Q4 2024 | $52.6M |
RPRX spent $262M buying back its own shares over the past year, down 78% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over RPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
RPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 5.4x | High |
| Q1 2020 | 2.2x | Moderate |
| Q4 2019 | 2.2x | Moderate |
RPRX's net debt is about 5.4 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over RPRX on leverage, with a lower net debt burden relative to earnings.
RPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.0 | Overbought |
| Stochastic | 89.9 | Overbought |
RPRX's weekly RSI is 74 (overbought) and its Stochastic is 90 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
RPRX PE vs Healthcare Sector
| Metric | RPRX | Sector median | Relative |
|---|---|---|---|
| PE | 45x | 26x | 76% above |
| PE % | 84 | 31 | 53 pts above |
RPRX is trading at 45x earnings, a 76% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over RPRX on valuation relative to its sector.
RPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.6 | 10% above |
| 20 week MA | $60.4 | 14% above |
| 50 week MA | $52.2 | 32% above |
| 100 week MA | $43.1 | 60% above |
| 200 week MA | $36.5 | 89% above |
RPRX has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
RPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $48.9 | -0.2% |
| 2021 | $48.9 | $40.3 | -18% |
| 2022 | $40.3 | $39.4 | -2% |
| 2023 | $39.4 | $28.1 | -29% |
| 2024 | $28.1 | $25.5 | -9.1% |
| 2025 | $25.5 | $39.2 | +54% |
| 2026 YTD | $39.2 | $69.0 | +76% |
RPRX has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.